B. Riley Financial Forecasts Strong Price Appreciation for Eton Pharmaceuticals (NASDAQ:ETON) Stock

Eton Pharmaceuticals (NASDAQ:ETON) had its price objective increased by investment analysts at B. Riley Financial from $26.00 to $31.00 in a research note issued to investors on Friday,Benzinga reports. The firm presently has a “buy” rating on the stock. B. Riley Financial’s target price would indicate a potential upside of 36.65% from the stock’s current price.

A number of other research firms have also recently issued reports on ETON. HC Wainwright lifted their target price on shares of Eton Pharmaceuticals from $35.00 to $37.00 and gave the company a “buy” rating in a research note on Monday, March 2nd. Craig Hallum raised their target price on shares of Eton Pharmaceuticals from $30.00 to $35.00 and gave the company a “buy” rating in a research note on Friday. Zacks Research upgraded Eton Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Thursday, January 1st. Wall Street Zen lowered Eton Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, December 13th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Eton Pharmaceuticals in a research report on Thursday, January 22nd. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Eton Pharmaceuticals currently has a consensus rating of “Hold” and an average target price of $39.33.

Eton Pharmaceuticals Stock Performance

Eton Pharmaceuticals stock traded up $1.92 during trading hours on Friday, reaching $22.69. 523,179 shares of the company were exchanged, compared to its average volume of 282,471. The company has a current ratio of 1.63, a quick ratio of 1.25 and a debt-to-equity ratio of 1.19. The stock has a 50-day moving average of $16.59 and a 200 day moving average of $17.34. The firm has a market cap of $608.41 million, a price-to-earnings ratio of -90.74 and a beta of 1.19. Eton Pharmaceuticals has a 12 month low of $11.09 and a 12 month high of $23.00.

Eton Pharmaceuticals (NASDAQ:ETON) last posted its quarterly earnings results on Thursday, March 19th. The company reported $0.05 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.12 by ($0.07). Eton Pharmaceuticals had a negative return on equity of 11.32% and a negative net margin of 9.50%.The company had revenue of $21.28 million during the quarter, compared to analyst estimates of $20.58 million. As a group, research analysts anticipate that Eton Pharmaceuticals will post -0.14 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. State of Alaska Department of Revenue acquired a new position in Eton Pharmaceuticals during the third quarter worth $30,000. Ameritas Investment Partners Inc. purchased a new stake in shares of Eton Pharmaceuticals during the 2nd quarter valued at $37,000. Quarry LP purchased a new stake in shares of Eton Pharmaceuticals during the 3rd quarter worth approximately $37,000. Legal & General Group Plc purchased a new stake in shares of Eton Pharmaceuticals during the 2nd quarter valued at approximately $41,000. Finally, Caitong International Asset Management Co. Ltd purchased a new stake in shares of Eton Pharmaceuticals in the fourth quarter worth about $44,000. Institutional investors own 27.86% of the company’s stock.

More Eton Pharmaceuticals News

Here are the key news stories impacting Eton Pharmaceuticals this week:

• Positive Sentiment: Analysts’ price targets show substantial upside — the mean target implies roughly a 49% upside versus the current share price, and Zacks notes analyst upgrades in estimates that can support further gains. Read More.
• Positive Sentiment: Revenue strength / record top‑line growth: Eton reported record Q4 revenue and beat consensus revenue estimates modestly, which supports the narrative of accelerating commercial traction in its rare‑disease portfolio. Read More.
• Neutral Sentiment: Earnings call materials and summaries are available for investors to assess management’s commentary on growth drivers and commercialization plans. Review the call summary for color on guidance and product rollouts. Read More.
• Neutral Sentiment: The full earnings call transcript is posted for detailed read‑through of management’s remarks and Q&A, useful for judging sustainability of revenue trends. Read More.
• Negative Sentiment: EPS miss and ongoing unprofitability: Eton reported $0.05 EPS versus a $0.12 consensus (miss of $0.07) and still posts a negative net margin and negative ROE, highlighting that profitability and cost control remain concerns despite revenue growth. Read More.
• Negative Sentiment: Analysts and media flagged the EPS shortfall in standalone coverage, which can weigh on near‑term sentiment even as estimates get revised upward. Read More.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.

The company’s product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.